Adage Capital Partners GP L.L.C. Has $3.84 Million Stock Position in Aligos Therapeutics, Inc. $ALGS

Adage Capital Partners GP L.L.C. raised its stake in shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS - Free Report) by 43.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 465,000 shares of the company's stock after buying an additional 140,000 shares during the period. Adage Capital Partners GP L.L.C. owned 7.61% of Aligos Therapeutics worth $3,836,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Tower Research Capital LLC TRC raised its holdings in Aligos Therapeutics by 2,073.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 652 shares of the company's stock valued at $26,000 after buying an additional 622 shares in the last quarter. Golden State Wealth Management LLC raised its holdings in Aligos Therapeutics by 100.0% during the first quarter. Golden State Wealth Management LLC now owns 5,348 shares of the company's stock valued at $44,000 after buying an additional 2,674 shares in the last quarter. AlphaQuest LLC bought a new position in Aligos Therapeutics during the first quarter valued at about $130,000. Northern Trust Corp bought a new position in Aligos Therapeutics during the fourth quarter valued at about $205,000. Finally, Readystate Asset Management LP bought a new position in Aligos Therapeutics during the first quarter valued at about $375,000. 60.43% of the stock is currently owned by institutional investors.

Aligos Therapeutics Stock Performance

Shares of Aligos Therapeutics stock traded down $0.69 during trading on Friday, reaching $10.20. The company's stock had a trading volume of 25,664 shares, compared to its average volume of 161,263. Aligos Therapeutics, Inc. has a one year low of $3.76 and a one year high of $46.80. The firm has a market cap of $62.70 million, a price-to-earnings ratio of -0.52 and a beta of 2.79. The business's fifty day moving average price is $9.09 and its 200-day moving average price is $8.16.

Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($1.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.35) by $0.82. Aligos Therapeutics had a negative return on equity of 22.41% and a negative net margin of 2,337.24%.The firm had revenue of $0.97 million for the quarter, compared to analyst estimates of $0.43 million. Sell-side analysts anticipate that Aligos Therapeutics, Inc. will post -10.36 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a "buy" rating and set a $50.00 target price on shares of Aligos Therapeutics in a report on Friday. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $50.00.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).